1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

Gilead Trial Pause Adds To Merck & Co’s HIV Concerns

Might Be End Of Partnership

 
• By Andrew McConaghie

The partners are halting recruitment out of “an abundance of caution,” but Gilead could decide to exit the alliance if islatravir cannot shake off safety concerns.

Gilead_USA
Gilead is closing in on approval for its long-acting HIV therapy, but the future of its combination with Merck's drug is now uncertain • Source: Alamy

Doubts about the future of Merck & Co’s long-acting HIV candidate islatravir have grown after a second trial has been paused in a matter of days, this time a combination study with Gilead Sciences’s lenacapavir.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

More from Therapy Areas

J&J’s Imaavy Approval Is The Starting Line For Pipeline-In-A-Product Strategy

 
• By Jessica Merrill

The company’s FcRn inhibitor nipocalimab was approved by the US FDA for generalized myasthenia gravis (gMG), where it will join a competitive market.

GSK Chief Optimistic About BD Despite Volatile Environment

 
• By Kevin Grogan

Emma Walmsley tells Scrip that the "biotech market is under a certain degree of pressure," so reasonably priced deals are available.

In Brief: AbbVie’s Rinvoq Secures US Approval For Giant Cell Arteritis

 
• By Sushmita Panda

JAK inhibitor gains ninth indication in US after a strong performance in the first quarter.